Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Lymphoma 16Lymphoma, Non-Hodgkin 11Lymphoma, Large B-Cell, Diffuse 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 7Hodgkin Disease 7Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myeloid, Acute 6Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Small Cell Lung Carcinoma 4Neuroblastoma 4Burkitt Lymphoma 4Testicular Neoplasms 3Sarcoma 3Lymphoma, T-Cell 3Leukemia 3Central Nervous System Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Waldenstrom Macroglobulinemia 2Testicular Germ Cell Tumor 2Teratoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Osteosarcoma 2Neoplasms, Germ Cell and Embryonal 2Myelodysplastic Syndromes 2Multiple Myeloma 2

Interventions

Amifostine 10Cisplatin 8Radiotherapy 7Etoposide 6Cyclophosphamide 4Carboplatin 4Paclitaxel 3pegfilgrastim 2camrelizumab 2apatinib 2Mitoxantrone 2Filgrastim 2Drug Therapy 2Cytarabine 2sodium thiosulfate 1sargramostim 1pazopanib 1icotinib 1glucarpidase 1etoposide phosphate 1denileukin diftitox 1Vitamin E 1Triptorelin Pamoate 1Tocopherols 1Thiotepa 1Tegafur 1Taxes 1Surgical Procedures, Operative 1Silymarin 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Drug-Related Side Effects and Adverse Reactions × etoposide phosphate × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡